Non-small-cell lung cancer: how to manage BRAF-mutated disease

18Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

BRAF mutations are reported in about 3–5% of non-small-cell lung cancer (NSCLC), almost exclusively in adenocarcinoma histology, and are classified into three different classes. The segmentation of BRAF mutations into V600 (class 1) and non-V600 (classes 2 and 3) relies on their biological characteristics and is of interest for predicting the therapeutic benefit of targeted therapies and immunotherapy. Given the relative rarity of this molecular subset of disease, evidence supporting treatment choices is limited. This review aims to offer a comprehensive update about available therapeutic options for patients with NSCLC harbouring BRAF mutations to guide the physician in the choice of treatment strategies. We collected the most relevant available data, from single-arm phase II studies and retrospective analyses conducted in advanced NSCLC, regarding the efficacy of BRAF and MEK inhibitors in both V600 and non-V600 BRAF mutations. We included case reports and smaller experiences that could provide information on specific alterations. With respect to immunotherapy, we reviewed retrospective evidence on immune-checkpoint inhibitors in this molecular subset, whereas data about chemo-immunotherapy in this molecular subgroup are lacking. Moreover, we included the available, though limited, retrospective evidence of immunotherapy as consolidation after chemo-radiation for unresectable stage III BRAF-mutant NSCLC, and an overview of ongoing clinical trials in the peri-operative setting that could open new perspectives in the future.

References Powered by Scopus

Mutations of the BRAF gene in human cancer

9022Citations
N/AReaders
Get full text

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

8121Citations
N/AReaders
Get full text

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

6645Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers

9Citations
N/AReaders
Get full text

Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments

4Citations
N/AReaders
Get full text

Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials

3Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Guaitoli, G., Zullo, L., Tiseo, M., Dankner, M., Rose, A. A. N., & Facchinetti, F. (2023). Non-small-cell lung cancer: how to manage BRAF-mutated disease. Drugs in Context. Bioexcel Publishing LTD. https://doi.org/10.7573/dic.2022-11-3

Readers over time

‘23‘24036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

75%

Lecturer / Post doc 1

25%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

40%

Biochemistry, Genetics and Molecular Bi... 2

40%

Chemistry 1

20%

Save time finding and organizing research with Mendeley

Sign up for free
0